{
  "model": "kimi-k2.5",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "All required output files have been written successfully. Here is the completion checklist:\n\n## Written Output Files Checklist\n\n| File | Status | Description |\n|------|--------|-------------|\n| ✅ `output/study_overview.json` | Written | Paper metadata, core research question, 5 cohorts with sample sizes, 5 major limitations |\n| ✅ `output/quantitative_findings.json` | Written | 6 quantitative findings (Q01-Q06) and 4 controls/null results with line references |\n| ✅ `output/claim_audit.json` | Written | 5 audited claims (C01-C05) with strength ratings, evidence quotes with line refs, and caveats |\n| ✅ `output/public_summary.json` | Written | Headline, plain-language summary, key innovations, caution notes, glossary (6 terms), and open questions |\n\n**All files:**\n- Use only relative paths as required\n- Contain valid JSON\n- Satisfy their respective schema constraints\n- Derive all content from `input/report.md`\n- Include proper line references (L19-L55) from the report\n- Use exact quotes where required by the schemas",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "accounts/fireworks/models/kimi-k2p5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.",
            "callId": "functions.read_file:0"
          }
        ],
        "usage": {
          "promptTokens": 549,
          "cachedTokens": 0,
          "responseTokens": 45,
          "totalTokens": 594
        },
        "costUsd": 0.0004644
      },
      {
        "step": 2,
        "modelVersion": "accounts/fireworks/models/kimi-k2p5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "functions.read_file:1"
          },
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": null
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "functions.list_directory:2"
          }
        ],
        "usage": {
          "promptTokens": 998,
          "cachedTokens": 512,
          "responseTokens": 93,
          "totalTokens": 1091
        },
        "costUsd": 0.0006218
      },
      {
        "step": 3,
        "modelVersion": "accounts/fireworks/models/kimi-k2p5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "functions.read_file:3"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "functions.read_file:4"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "functions.read_file:5"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 1000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "functions.read_file:6"
          }
        ],
        "usage": {
          "promptTokens": 2195,
          "cachedTokens": 512,
          "responseTokens": 155,
          "totalTokens": 2350
        },
        "costUsd": 0.001526
      },
      {
        "step": 4,
        "modelVersion": "accounts/fireworks/models/kimi-k2p5",
        "text": "Now I'll create all four required JSON output files based on the report content and schemas.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of mRNA vaccines create an interferon-rich inflammatory state that improves tumor sensitivity to anti-PD-L1 checkpoint blockade therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled across repeat experiments testing intratumoral mRNA vaccine combined with anti-PD-L1 checkpoint blockade.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Pooled across matched controls including vaccine only, ICI only, and vehicle treatment arms.\"\n    },\n    {\n      \"id\": \"human-retrospective-total\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, analyzed by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective cohort who had received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective cohort with no prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "functions.write_file:7"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "functions.write_file:8"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling that primes tumors for improved response to immune checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination induces a broader peptide repertoire display on MHC-I, enhancing tumor visibility to T cells and increasing CD8+ T-cell infiltration.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"mRNA vaccination increases PD-L1 expression in tumor tissue, making the checkpoint axis more targetable and creating a biological rationale for combination with anti-PD-L1 therapy.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation from the retrospective human data.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Patients with prior SARS-CoV-2 mRNA vaccination showed improved survival under ICI treatment compared to unvaccinated patients in retrospective analysis.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"The retrospective design means residual confounding is likely, vaccination timing relative to ICI initiation varied across patients, and tumor-type heterogeneity limits causal inference.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"The combination of intratumoral mRNA vaccination with anti-PD-L1 checkpoint blockade improves tumor control in preclinical models.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\",\n          \"line_ref\": \"L19\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, and prospective randomized studies are required before clinical protocol changes are justified.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "functions.write_file:9"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA Vaccines Show Promise in Making Tumors More Responsive to Cancer Immunotherapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors are powerful cancer drugs that help the immune system recognize and attack tumors, but they don't work well for many patients because some tumors are 'invisible' to immune cells. This study investigated whether mRNA vaccines, similar to those used for COVID-19, could be delivered directly into tumors to make them more sensitive to immunotherapy. In laboratory experiments with mice, injecting mRNA into tumors triggered an immune alarm system (called type I interferon response) that made cancer cells display more signals on their surface, helping immune cells find them. When combined with checkpoint inhibitor drugs, this approach improved tumor control. The researchers also analyzed medical records of cancer patients who had received COVID-19 mRNA vaccines before immunotherapy and found they had better survival outcomes than unvaccinated patients. However, this human data comes from a retrospective analysis, not a randomized trial, so it cannot prove cause-and-effect. The findings suggest a promising biological mechanism but require confirmation in prospective clinical trials before changing treatment protocols.\",\n  \"what_is_new\": [\n    \"mRNA vaccines can be delivered directly into tumors to create an inflammatory environment that primes the immune system for better response to checkpoint blockade drugs.\",\n    \"Prior SARS-CoV-2 mRNA vaccination in cancer patients was associated with improved survival during subsequent immunotherapy treatment.\",\n    \"The sensitization mechanism involves type I interferon signaling that expands the tumor antigen display on MHC-I molecules, making cancer cells more visible to CD8+ T cells while simultaneously increasing PD-L1 expression to create a targetable checkpoint axis.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human survival data comes from a retrospective analysis of patient records, not a randomized controlled trial, so hidden factors (confounding variables) may explain the observed association.\",\n    \"Timing of vaccination relative to cancer treatment varied among patients, making it difficult to determine the optimal schedule for any potential benefit.\",\n    \"The patient group included mixed cancer types and treatment histories, so results may not apply equally to all cancers.\",\n    \"Mouse tumor models do not perfectly replicate human cancers, so laboratory findings may not translate directly to human patients.\",\n    \"Some of the biological mechanism data was strongest only in specific experimental models rather than consistently across all tested systems.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitors (ICIs)\",\n      \"definition\": \"Drugs that block proteins like PD-L1 that tumors use to put brakes on immune cell attacks, allowing T cells to kill cancer cells more effectively.\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine using messenger RNA molecules that instruct cells to make specific proteins, triggering an immune response against those proteins.\"\n    },\n    {\n      \"term\": \"MHC-I peptidome\",\n      \"definition\": \"The collection of protein fragments (peptides) displayed on the surface of cells by MHC class I molecules, which allows immune cells to survey what is inside the cell.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of signaling proteins produced by cells in response to viral infections or other threats that activate immune defenses and inflammation.\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"A type of immune cell (cytotoxic T lymphocyte) that recognizes and kills cancer cells or infected cells displaying specific antigens on their surface.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that some cancer cells display to interact with PD-1 on T cells and suppress immune attack; blocking this interaction is the target of checkpoint inhibitor therapy.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will prospective randomized clinical trials confirm that mRNA vaccination improves immunotherapy outcomes, and what is the optimal timing and dosing schedule?\",\n    \"Which specific cancer types are most likely to benefit from mRNA vaccination as a sensitization strategy?\",\n    \"Can intratumoral mRNA delivery be practically implemented in human patients across different tumor locations and stages?\",\n    \"What are the long-term safety implications of combining mRNA vaccines with checkpoint blockade therapy?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "functions.write_file:10"
          }
        ],
        "usage": {
          "promptTokens": 5315,
          "cachedTokens": 2048,
          "responseTokens": 3818,
          "totalTokens": 9133
        },
        "costUsd": 0.013619000000000001
      },
      {
        "step": 5,
        "modelVersion": "accounts/fireworks/models/kimi-k2p5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 100
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral delivery of mRNA vaccines create an interferon-rich inflammatory state that improves tumor sensitivity to anti-PD-L1 checkpoint blockade therapy?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combo\",\nL13:       \"label\": \"Mouse efficacy cohort (combination therapy)\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Pooled across repeat experiments testing intratumoral mRNA vaccine combined with anti-PD-L1 checkpoint blockade.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Pooled across matched controls including vaccine only, ICI only, and vehicle treatment arms.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-total\",\nL25:       \"label\": \"Human retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, analyzed by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subset of the retrospective cohort who had received prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subset of the retrospective cohort with no prior SARS-CoV-2 mRNA vaccination before ICI treatment.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "functions.read_file:11"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 100
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "functions.read_file:12"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 100
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling that primes tumors for improved response to immune checkpoint blockade.\",\nL6:       \"strength\": \"strong\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL10:           \"line_ref\": \"L31\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL14:           \"line_ref\": \"L39\"\nL15:         },\nL16:         {\nL17:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL18:           \"line_ref\": \"L42\"\nL19:         }\nL20:       ],\nL21:       \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and mouse model effects may not map one-to-one to all human tumors.\"\nL22:     },\nL23:     {\nL24:       \"claim_id\": \"C02\",\nL25:       \"claim\": \"mRNA vaccination induces a broader peptide repertoire display on MHC-I, enhancing tumor visibility to T cells and increasing CD8+ T-cell infiltration.\",\nL26:       \"strength\": \"strong\",\nL27:       \"evidence\": [\nL28:         {\nL29:           \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\nL30:           \"line_ref\": \"L28\"\nL31:         },\nL32:         {\nL33:           \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\nL34:           \"line_ref\": \"L29\"\nL35:         },\nL36:         {\nL37:           \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\nL38:           \"line_ref\": \"L33\"\nL39:         }\nL40:       ],\nL41:       \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL42:     },\nL43:     {\nL44:       \"claim_id\": \"C03\",\nL45:       \"claim\": \"mRNA vaccination increases PD-L1 expression in tumor tissue, making the checkpoint axis more targetable and creating a biological rationale for combination with anti-PD-L1 therapy.\",\nL46:       \"strength\": \"moderate\",\nL47:       \"evidence\": [\nL48:         {\nL49:           \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\nL50:           \"line_ref\": \"L32\"\nL51:         },\nL52:         {\nL53:           \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\nL54:           \"line_ref\": \"L45\"\nL55:         }\nL56:       ],\nL57:       \"caveat\": \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation from the retrospective human data.\"\nL58:     },\nL59:     {\nL60:       \"claim_id\": \"C04\",\nL61:       \"claim\": \"Patients with prior SARS-CoV-2 mRNA vaccination showed improved survival under ICI treatment compared to unvaccinated patients in retrospective analysis.\",\nL62:       \"strength\": \"tentative\",\nL63:       \"evidence\": [\nL64:         {\nL65:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL66:           \"line_ref\": \"L30\"\nL67:         },\nL68:         {\nL69:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL70:           \"line_ref\": \"L49\"\nL71:         }\nL72:       ],\nL73:       \"caveat\": \"The retrospective design means residual confounding is likely, vaccination timing relative to ICI initiation varied across patients, and tumor-type heterogeneity limits causal inference.\"\nL74:     },\nL75:     {\nL76:       \"claim_id\": \"C05\",\nL77:       \"claim\": \"The combination of intratumoral mRNA vaccination with anti-PD-L1 checkpoint blockade improves tumor control in preclinical models.\",\nL78:       \"strength\": \"strong\",\nL79:       \"evidence\": [\nL80:         {\nL81:           \"quote\": \"Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\",\nL82:           \"line_ref\": \"L19\"\nL83:         },\nL84:         {\nL85:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL86:           \"line_ref\": \"L46\"\nL87:         }\nL88:       ],\nL89:       \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, and prospective randomized studies are required before clinical protocol changes are justified.\"\nL90:     }\nL91:   ]\nL92: }",
            "callId": "functions.read_file:13"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 100
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA Vaccines Show Promise in Making Tumors More Responsive to Cancer Immunotherapy\",\nL3:   \"plain_language_summary\": \"Immune checkpoint inhibitors are powerful cancer drugs that help the immune system recognize and attack tumors, but they don't work well for many patients because some tumors are 'invisible' to immune cells. This study investigated whether mRNA vaccines, similar to those used for COVID-19, could be delivered directly into tumors to make them more sensitive to immunotherapy. In laboratory experiments with mice, injecting mRNA into tumors triggered an immune alarm syst\nL4:   \"what_is_new\": [\nL5:     \"mRNA vaccines can be delivered directly into tumors to create an inflammatory environment that primes the immune system for better response to checkpoint blockade drugs.\",\nL6:     \"Prior SARS-CoV-2 mRNA vaccination in cancer patients was associated with improved survival during subsequent immunotherapy treatment.\",\nL7:     \"The sensitization mechanism involves type I interferon signaling that expands the tumor antigen display on MHC-I molecules, making cancer cells more visible to CD8+ T cells while simultaneously increasing PD-L1 expression to create a targetable checkpoint axis.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human survival data comes from a retrospective analysis of patient records, not a randomized controlled trial, so hidden factors (confounding variables) may explain the observed association.\",\nL11:     \"Timing of vaccination relative to cancer treatment varied among patients, making it difficult to determine the optimal schedule for any potential benefit.\",\nL12:     \"The patient group included mixed cancer types and treatment histories, so results may not apply equally to all cancers.\",\nL13:     \"Mouse tumor models do not perfectly replicate human cancers, so laboratory findings may not translate directly to human patients.\",\nL14:     \"Some of the biological mechanism data was strongest only in specific experimental models rather than consistently across all tested systems.\"\nL15:   ],\nL16:   \"glossary\": [\nL17:     {\nL18:       \"term\": \"Immune checkpoint inhibitors (ICIs)\",\nL19:       \"definition\": \"Drugs that block proteins like PD-L1 that tumors use to put brakes on immune cell attacks, allowing T cells to kill cancer cells more effectively.\"\nL20:     },\nL21:     {\nL22:       \"term\": \"mRNA vaccine\",\nL23:       \"definition\": \"A vaccine using messenger RNA molecules that instruct cells to make specific proteins, triggering an immune response against those proteins.\"\nL24:     },\nL25:     {\nL26:       \"term\": \"MHC-I peptidome\",\nL27:       \"definition\": \"The collection of protein fragments (peptides) displayed on the surface of cells by MHC class I molecules, which allows immune cells to survey what is inside the cell.\"\nL28:     },\nL29:     {\nL30:       \"term\": \"Type I interferon\",\nL31:       \"definition\": \"A family of signaling proteins produced by cells in response to viral infections or other threats that activate immune defenses and inflammation.\"\nL32:     },\nL33:     {\nL34:       \"term\": \"CD8+ T cells\",\nL35:       \"definition\": \"A type of immune cell (cytotoxic T lymphocyte) that recognizes and kills cancer cells or infected cells displaying specific antigens on their surface.\"\nL36:     },\nL37:     {\nL38:       \"term\": \"PD-L1\",\nL39:       \"definition\": \"A protein that some cancer cells display to interact with PD-1 on T cells and suppress immune attack; blocking this interaction is the target of checkpoint inhibitor therapy.\"\nL40:     }\nL41:   ],\nL42:   \"open_questions\": [\nL43:     \"Will prospective randomized clinical trials confirm that mRNA vaccination improves immunotherapy outcomes, and what is the optimal timing and dosing schedule?\",\nL44:     \"Which specific cancer types are most likely to benefit from mRNA vaccination as a sensitization strategy?\",\nL45:     \"Can intratumoral mRNA delivery be practically implemented in human patients across different tumor locations and stages?\",\nL46:     \"What are the long-term safety implications of combining mRNA vaccines with checkpoint blockade therapy?\"\nL47:   ]\nL48: }",
            "callId": "functions.read_file:14"
          }
        ],
        "usage": {
          "promptTokens": 9027,
          "cachedTokens": 5120,
          "responseTokens": 153,
          "totalTokens": 9180
        },
        "costUsd": 0.0033152
      },
      {
        "step": 6,
        "modelVersion": "accounts/fireworks/models/kimi-k2p5",
        "text": "All required output files have been written successfully. Here is the completion checklist:\n\n## Written Output Files Checklist\n\n| File | Status | Description |\n|------|--------|-------------|\n| ✅ `output/study_overview.json` | Written | Paper metadata, core research question, 5 cohorts with sample sizes, 5 major limitations |\n| ✅ `output/quantitative_findings.json` | Written | 6 quantitative findings (Q01-Q06) and 4 controls/null results with line references |\n| ✅ `output/claim_audit.json` | Written | 5 audited claims (C01-C05) with strength ratings, evidence quotes with line refs, and caveats |\n| ✅ `output/public_summary.json` | Written | Headline, plain-language summary, key innovations, caution notes, glossary (6 terms), and open questions |\n\n**All files:**\n- Use only relative paths as required\n- Contain valid JSON\n- Satisfy their respective schema constraints\n- Derive all content from `input/report.md`\n- Include proper line references (L19-L55) from the report\n- Use exact quotes where required by the schemas",
        "toolCalls": [],
        "usage": {
          "promptTokens": 12977,
          "cachedTokens": 8704,
          "responseTokens": 497,
          "totalTokens": 13474
        },
        "costUsd": 0.0049252
      }
    ],
    "totalCostUsd": 0.024471600000000003
  }
}
